Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Cost of Revenue: 2020-2025

Historic Cost of Revenue for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Sep 2025 value amounting to $36.0 million.

  • Maravai Lifesciences Holdings' Cost of Revenue fell 2.22% to $36.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.9 million, marking a year-over-year increase of 2.07%. This contributed to the annual value of $150.9 million for FY2024, which is 1.43% up from last year.
  • Maravai Lifesciences Holdings' Cost of Revenue amounted to $36.0 million in Q3 2025, which was down 9.22% from $39.6 million recorded in Q2 2025.
  • In the past 5 years, Maravai Lifesciences Holdings' Cost of Revenue registered a high of $53.3 million during Q4 2022, and its lowest value of $31.4 million during Q1 2021.
  • In the last 3 years, Maravai Lifesciences Holdings' Cost of Revenue had a median value of $37.2 million in 2024 and averaged $37.7 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first skyrocketed by 105.21% in 2021, then plummeted by 34.07% in 2023.
  • Maravai Lifesciences Holdings' Cost of Revenue (Quarterly) stood at $39.1 million in 2021, then spiked by 36.06% to $53.3 million in 2022, then plummeted by 34.07% to $35.1 million in 2023, then grew by 5.87% to $37.2 million in 2024, then fell by 2.22% to $36.0 million in 2025.
  • Its Cost of Revenue was $36.0 million in Q3 2025, compared to $39.6 million in Q2 2025 and $39.1 million in Q1 2025.